Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets

Experimental Neurology

Volumn 211, Issue 1, 2008, Pages 172-179

  Stockwell, K A ^a   Virley, D J ^b   Perren, M ^b   Iravani, M M ^a   Jackson, M J ^a   Rose, S ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Common marmosets; Continuous delivery; Dyskinesia; MPTP; Parkinson's disease; Ropinirole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA; ROPINIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DYSKINESIA; FEMALE; LOCOMOTION; MARMOSET; MINIPUMP; MOTOR DYSFUNCTION; NONHUMAN; OSMOTIC PUMP; PARKINSON DISEASE; PRIORITY JOURNAL; STANDARD;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CALLITHRIX; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; MOTOR ACTIVITY; MOVEMENT DISORDERS; MPTP POISONING; TIME FACTORS;

EID: 42749085138     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.01.019     Document Type: Article

References (41)

1. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., Taylor R.L., Sanchez-Ramos J., and O'Brien C.F. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49 (1997) 393-399
2. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2 (2001) 577-588
3. Bibbiani F., Costantini L.C., Patel R., and Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 192 (2005) 73-78
4. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Di P.T., Walters R.R., and Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272 (1995) 854-859
5. Calon F., and Di P.T. Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat. Disord. 8 (2002) 449-454
6. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di P.T., and Bedard P.J. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47 (2000) S70-S78
7. Calon F., Hadj T.A., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di P.T., and Bedard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23 (2000) S92-S100
8. Chen L., Togasaki D.M., Langston J.W., Di Monte D.A., and Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience 132 (2005) 409-420
9. Critchley P.H., Grandas P.F., Quinn N.P., Parkes J.D., and Marsden C.D. Continuous subcutaneous lisuride infusions in Parkinson's disease. J. Neural Transm., Suppl. 27 (1988) 55-60
10. Curran M.P., and Perry C.M. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 64 (2004) 2125-2141
11. Dunnett S. L-DOPA, dyskinesia and striatal plasticity. Nat. Neurosci. 6 (2003) 437-438
12. Hubble J.P. Long-term studies of dopamine agonists. Neurology 58 (2002) S42-S50
13. Inzelberg R., Schechtman E., and Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 20 (2003) 847-855
14. Jackson M.J., Smith L.A., Al-Barghouthy G., Rose S., and Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp. Neurol. 204 (2006) 162-170
15. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 Suppl. 11 (2005) S11-S16
16. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. 247 Suppl. 2 (2000) II43-II50
17. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62 (2004) S47-S55
18. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., Watt H., Bhatia K., Quinn N., and Lees A.J. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 20 (2005) 151-157
19. Maratos E.C., Jackson M.J., Pearce R.K., and Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord. 16 (2001) 631-641
20. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., and Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol. 179 (2003) 90-102
21. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin. Pharmacokinet. 45 (2006) 109-136
22. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernas H., Nystrom C., and Aquilonius S.M. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol. 26 (2003) 156-163
23. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., Aquilonius S.M., and Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
24. Obeso J.A., Grandas F., Vaamonde J., Luquin M.R., Artieda J., Lera G., Rodriguez M.E., and Martinez-Lage J.M. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39 (1989) 11-19
25. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
26. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., and Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology 55 (2000) S13-S20
27. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann. Neurol. 47 (2000) S22-S32
28. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., Grosset D.G., Arnold G., Leenders K.L., Hundemer H.P., Lledo A., Wood A., Frewer P., and Schwarz J. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov. Disord. 21 (2006) 343-353
29. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 (2006) 677-687
30. Pearce R.K., Jackson M., Smith L., Jenner P., and Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord. 10 (1995) 731-740
31. Pearce R.K., Banerji T., Jenner P., and Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 13 (1998) 234-241
32. Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L.C., Senthilselvan A., and Hornykiewicz O. Clinical-pathological study of levodopa complications. Mov. Disord. 17 (2002) 289-296
33. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 (2000) 1484-1491
34. Reynolds N.A., Wellington K., and Easthope S.E. Rotigotine: in Parkinson's disease. CNS Drugs 19 (2005) 973-981
35. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., Montastruc J.L., and Marsden C.D. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl. 1 (1998) 23-30
36. Smith L., De S.M., Jenner P., and Marsden C.D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov. Disord. 11 (1996) 125-135
37. Smith L.A., Tel B.C., Jackson M.J., Hansard M.J., Braceras R., Bonhomme C., Chezaubernard C., Del Signore S., Rose S., and Jenner P. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov. Disord. 17 (2002) 887-901
38. Stocchi F., and Olanow C.W. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 62 (2004) S56-S63
39. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 (2002) 2058-2066
40. Stocchi F., Vacca L., Ruggieri S., and Olanow C.W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. 62 (2005) 905-910
41. Vaamonde J., Luquin M.R., and Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 114 Pt 1B (1991) 601-617